Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Minghui grants ASKA Japanese rights to sub-q TED candidate in $440M deal

4 November 2026 · By · Wire by Fusion42

Published

4 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

Japan

◆ Source

Read at fiercebiotech.com →

◆ Verified

Fusion42 · 4 November 2026 · Fusion42 review

Minghui has granted ASKA exclusive rights in Japan for a subcutaneous teduglutide (TED) candidate under a deal valued at $440 million.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Your biotech firm should consider Japan as an open market for licensing opportunities in subcutaneous treatments. This deal signals Japanese partners are willing to invest heavily in novel delivery methods for established therapies.

◆ Coverage

1 source · 4 Nov 2026

◆ Related on Wire

◆ Topics

Biotechpharma-deallicensingjapan-marketbiotechdrug-development